Re-defining standards of care in resectable head and neck squamous cell carcinoma—lessons from KEYNOTE-689 and NIVOPOSTOP

By Saral Mehra, S. S. Yom, B. Burtness. 2025

Subfields: Oncology, Otorhinolaryngology

Citations in the corpus

• TROP2 expression in head and neck squamous cell carcinoma: association with the tumor immune microenvironment and clinical outcome (2026, unknown): “More recently, the phase III KEYNOTE-689 trial further extended the bene fi t of PD-1 inhibition into the perioperative setting in locally advanced disease (8, 57).”